Netherlands· NL-fc79c167cd06

Nintedanib CF 150 mg, zachte capsules

A nintedanib product containing nintedanibesilaat, registered in Netherlands by Centrafarm B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC L01EX09

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about nintedanibesilaatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Nintedanib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EX09 (nintedanib), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
7 of them publish a price we can compare per daily dose

Search nintedanib products by name

Nintedanib · ATC L01EX09

14 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Germany
Icelandprice
Ireland
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of nintedanib costs, country by country.

Normalised to the WHO defined daily dose (0.38 g), so markets compare like for like.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown
US figures are pharmacy acquisition cost (CMS NADAC), not retail

Open the full comparison — free account Drug prices for market access

Nintedanib · price per daily dose (0.38 g)

USD · FX 28 Sept 2026

US United States$51.13 (acquisition cost)
CH Switzerland$34.12

Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: NINTEDANIBESILAAT
Manufacturer: Centrafarm B.V.
Country: Netherlands (NL)
ATC code: L01EX09
ATC class: Nintedanib
Defined daily dose: 0.38 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
130842

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

160 interactions on record for nintedanib.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check nintedanib against other medicines How interaction checks work

Nintedanib · interactions on record

160 records

21 severe
139 moderate

Most severe, free to view

MipomersenC10AX11severe
LomitapideC10AX12severe
DexamethasoneH02AB02severe
RifampicinJ04AB02severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nintedanib in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nintedanib products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

Austria · Nintedanib Cipla, Nintedanib Ratiopharm
Belgium · Nintedanib Accordpharma, Nintedanib Eg
Cyprus · Nintedanib Teva
Czechia · Nintedanib Glenmark, Nintedanib Sandoz
Germany · Nintedanib, Nintedanib 1 A Pharma
Denmark · Nintedanib "sandoz", Nintedanib Glenmark
Estonia · Agarf, Nintedanib Sandoz
Spain · Nintedanib, Nintedanib Accordpharma
Finland · Nintedanib Glenmark, Nintedanib Ratiopharm
France · Nintedanib Arrow, Nintedanib Biogaran
United Kingdom (Northern Ireland) · Nintedanib, Nintedanib Accord Healthcare
Greece · Nifib, Nindraf
Croatia · Gevesla, Nintedanib Accordpharma
Hungary · Nintedanib Accordpharma, Nintedanib Onkogen
Ireland · Nintedanib Accordpharma, Nintedanib Clonmel
Iceland · Agarf, Nintedanib Accord
Italy · Nintedanib Accordpharma, Nintedanib Aurobindo
Liechtenstein · Nintedanib Accord, Nintedanib Viatris
Lithuania · Agarf, Nintedanib Sandoz
Luxembourg · Nintedanib Eg, Nintedanib Eurogenerics
Latvia · Agarf, Nintedanib Sandoz
Malta · Nifiden Adalvo, Nintedanib Adalvo
Norway · Nintedanib Accord, Nintedanib Devatis
Poland · Nintedanib, Nintedanib Accordpharma
Portugal · Nintedanib Accordpharma, Nintedanib Eugia
Romania · Gevesla, Nintedanib Dr. Reddy’s
Sweden · Nintedanib Devatis, Nintedanib Glenmark
Slovenia · Nintedanib Accordpharma, Nintedanib Stada
Slovakia · Nintedanib Stada, Nintedanib Teva

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/aec6b61a-ec90-4dcf-bb78-932b8ac38322
GET /v1/drugs/aec6b61a-ec90-4dcf-bb78-932b8ac38322?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, zacht",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h130842_smpc.pdf",
  "strength": null,
  "atc_label": "Nintedanib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg130842",
  "excipients": [
    "AMMONIA (E 527)",
    "GELATINE (E 441)",
    "GLYCEROL 85 PER CENT (E 422)",
    "HARD VET",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "POLYGLYCERYL-3 OLEAAT (E 475)",
    "PROPYLEENGLYCOL (E 1520)",
    "SCHELLAK GLAZE, GEDEELTELIJK VERESTERD",
    "TITAANDIOXIDE (E 171)",
    "TRIGLYCERIDEN MIDDELLANGE KETEN",
    "WATER, GEZUIVERD",
    "ZWARTE INKT"
  ],
  "substances": [
    "NINTEDANIBESILAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h130842.pdf",
  "authorised_at": "2024/02/02",
  "procedure_number": "IS/H/0545/002",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "130842",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about nintedanib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console